Key features and details
- Rabbit polyclonal to TNFAIP3
- Suitable for: WB, IP
- Reacts with: Human
- Isotype: IgG
Product nameAnti-TNFAIP3 antibody
See all TNFAIP3 primary antibodies
DescriptionRabbit polyclonal to TNFAIP3
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
- HeLa whole cell lysate (ab150035)
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7
Preservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab93868 was affinity purified using an epitope specific to TNFAIP3 immobilized on solid support.
Our Abpromise guarantee covers the use of ab93868 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: 1/2000 - 1/10000. Predicted molecular weight: 90 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionUbiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. In vitro able to deubiquitinate both 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system.
Sequence similaritiesBelongs to the peptidase C64 family.
Contains 7 A20-type zinc fingers.
Contains 1 OTU domain.
DomainThe A20-type zinc fingers mediate the ubiquitin ligase activity.
The OTU domain mediates the deubiquitinase activity.
Cellular localizationCytoplasm. Nucleus.
- Information by UniProt
- A20 antibody
- AISBL antibody
- MGC104522 antibody
All lanes : Anti-TNFAIP3 antibody (ab93868) at 0.1 µg/ml
Lane 1 : HeLa whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : HeLa whole cell lysate at 5 µg
Developed using the ECL technique.
Predicted band size: 90 kDa
Exposure time: 3 minutes
ab93868, at 1 µg/ml, detecting TNFAIP3 in HeLa whole cell lysate by WB of IP.
Lane 1: IP with ab93868 at 3 µg/mg of lysate.
Lane 2: Control IgG.
1 mg of lysate was used for IP and 20% of the IP was loaded.
Detection: Chemiluminescence an with exposure time of 30 seconds.
ab93868 has not yet been referenced specifically in any publications.